Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range

Circulating miR-371a-3p has excellent performance in the detection of viable (non-teratoma) GCT pre-orchiectomy; however, its ability to detect occult disease is understudied. To refine the serum miR-371a-3p assay in the minimal residual disease setting we compared performance of raw (Cq) and normal...

Full description

Saved in:
Bibliographic Details
Published inResearch square
Main Authors Lafin, John, Scarpini, Cinzia, Amini, Armon, Konneh, Bendu, Howard, Jeffrey, Gerald, Thomas, Nuno, Michelle, Piao, Jin, Savelyeva, Anna, Wang, Zhaohui, Gagan, Jeffrey, Jia, Liwei, Lewis, Cheryl, Murray, Sarah, Sawa, Yun, Margulis, Vitaly, Woldu, Solomon, Strand, Douglas, Coleman, Nicholas, Amatruda, James, Frazier, Lindsay, Murray, Matthew, Bagrodia, Aditya
Format Journal Article
LanguageEnglish
Published United States 21.03.2023
Online AccessGet more information

Cover

Loading…
More Information
Summary:Circulating miR-371a-3p has excellent performance in the detection of viable (non-teratoma) GCT pre-orchiectomy; however, its ability to detect occult disease is understudied. To refine the serum miR-371a-3p assay in the minimal residual disease setting we compared performance of raw (Cq) and normalized (∆Cq, RQ) values from prior assays, and validated interlaboratory concordance by aliquot swapping. Revised assay performance was determined in a cohort of 32 patients suspected of occult retroperitoneal disease. Assay superiority was determined by comparing resulting receiver-operator characteristic (ROC) curves using the Delong method. Pairwise t-tests were used to test for interlaboratory concordance. Performance was comparable when thresholding based on raw Cq normalized values. Interlaboratory concordance of miR-371a-3p was high, but reference genes miR-30b-5p and cel-miR-39-3p were discordant. Introduction of an indeterminate range of Cq 28-35 with a repeat run for any indeterminate improved assay accuracy from 0.84 to 0.92 in a group of patients suspected of occult GCT. We recommend that serum miR-371a-3p test protocols are updated to a) utilize threshold-based approaches using raw Cq values, b) continue to include an endogenous (e.g., miR-30b-5p) and exogenous non-human spike-in (e.g., cel-miR-39-3p) microRNA for quality control, and c) to re-run any sample with an indeterminate result.
DOI:10.21203/rs.3.rs-2644890/v1